Meet our team

Founded by physician scientists and led by experienced diagnostics executives, Droplet is innovating in places others have overlooked. We are based in Cambridge, MA. Our lead funder is The Engine, a venture capital firm launched by MIT to invest in companies tackling the world’s most urgent challenges.

Leadership

Theresa-trimble-photo
Theresa Tribble
Co-founder and CEO

KNOW MORE

Theresa Tribble
Co-founder and CEO
Theresa Tribble has spent the past 20 years building early-stage life science companies. She served as Chief Business Officer of Everlywell, the leader in at-home testing and helped found BigHat Biosciences and Landsdowne Labs. Theresa earned her undergraduate degree at Wellesley College and her MBA at Harvard Business School.
Wendy-winckler-photo
Wendy Winckler, PhD
Chief Scientific Officer

KNOW MORE

Wendy Winckler, PhD
Chief Scientific Officer
Wendy Winckler has over 20 years of genomics experience, including serving as CSO for Glympse Bio. She led Oncology Next Generation Diagnostics at Novartis and numerous early cancer genome studies at the Broad Institute. Dr. Winckler holds a BS in microbiology and molecular genetics from UCLA and a PhD in genetics from Harvard.
Jose-zevallos-photo
Jose P. Zevallos, MD, MPH
Scientific Co-founder

KNOW MORE

Jose P. Zevallos, MD, MPH
Scientific Co-founder
Jose P. Zevallos is Chair of Otolaryngology at UPMC. He previously served as Division Chief and Professor of Head & Neck Surgical Oncology at Washington University in St. Louis. He has published over 120 peer-reviewed articles and is a frequent speaker at conferences in his field. Dr. Zevallos earned a Biology degree from Middlebury and a medical degree from Rutgers.
Aadel-chaudhuri-photo
Aadel Chaudhuri, MD, PhD
Scientific Co-founder

KNOW MORE

Aadel Chaudhuri, MD, PhD
Scientific Co-founder
Aadel Chaudhuri is Assistant Professor of Radiation Oncology and leads the Chaudhuri Lab at Washington University in St. Louis, where his clinical practice focuses on lung cancer. He is highly published in the ctDNA field. Dr. Chaudhuri completed his undergraduate studies at MIT, his PhD at CalTech, and his medical degree at Stanford.
Stan Lapidus
Stan Lapidus
Co-founder

KNOW MORE

Stan Lapidus
Co-founder
Stan Lapidus serves on the board of directors at Droplet. He founded Cytyc Corp, which revolutionized cervical cancer screening through the ThinPrep pap test, and Exact Sciences, which did the same for colon cancer screening. Stan holds 37 patents and is a fellow of the American Institute of Medical and Biological Engineering.

Team

Ashley Tellis website 2
Ashley Tellis
Principal Research Associate

View Profile

Abbey Crittenden
Abbey Crittenden
Clinical Operations Manager

View Profile

Seka Lazare
Seka Lazare, PhD
Director of Assay Development

View Profile

Adam Benson
Adam Benson
Senior Director of Clinical Operations

View Profile

pam-baker-photo
Pamela Baker
Chief of Staff

View Profile

marra-francis-photo
Marra Francis, MD
Medical Advisor

View Profile

Zhuosheng-Gu-photo-new
Zhuosheng Gu
Director of Informatics

View Profile

Adam Harmon
Adam Harmon
Bioinformatics Scientist

View Profile

Molly-Hurley-photo
Molly Hurley
Associate Director of Clinical and Medical Affairs

View Profile

Megan-Long-photo
Megan Long
Research Technician

View Profile

Jason-Pulsifer-photo
Jason Pulsifer
Vice President of Finance and Operations

View Profile

Maciej-Pacula-photo
Maciej Pacula
Data Analyst

View Profile

Advisors

Yuri Maricich, MD

View Profile

Catherine Sabatos-Peyton, PhD

View Profile

Peter Slavin, MD

View Profile

Siraj Ali, MD, PhD

View Profile

Mark DePristo, PhD

View Profile

Nathan Hunkapiller, PhD

View Profile

Press

Unveiling Liquid Gold: Lymph as an HPV Marker in OPSCC to Guide Treatment Decisions
A Liquid Biopsy for Local Recurrences
Droplet Biosciences Releases First Research Data, Demonstrates Lymph Liquid Biopsy‘s Ability to Predict Locoregional Recurrence
Droplet Biosciences Announces Lymph Diagnostic Platform to Help Prevent Cancer Recurrence
Droplet Biosciences Targets Lymph Fluid in New Residual Cancer Detection Strategy